Methods of hormonal treatment utilizing ascending-dose extended cycle regimens

Details for Australian Patent Application No. 2005294269 (hide)

Owner Teva Women's Health, Inc.

Inventors Bronnenkant, Lance J.; Reape, Kathleen Z.; Diliberti, Charles E.

Agent Davies Collison Cave

Pub. Number AU-B-2005294269

PCT Pub. Number WO2006/042021

Priority 60/684,568 26.05.05 US; 60/616,424 07.10.04 US

Filing date 7 October 2005

Wipo publication date 20 April 2006

Acceptance publication date 28 July 2011

International Classifications

A61K 31/56 (2006.01) - Compounds containing cyclopenta[a]hydrophenanthrene ring systems

A61K 31/565 (2006.01) - not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol

A61K 31/567 (2006.01) - substituted in position 17 alpha, e.g. mestranol, norethandrolone

A61P 15/18 (2006.01) Drugs for genital or sexual disorders

Event Publications

24 May 2007 PCT application entered the National Phase

  PCT publication WO2006/042021 Priority application(s): WO2006/042021

26 August 2010 Alteration of Name

  The name of the applicant has been altered to Teva Women's Health, Inc.

28 July 2011 Application Accepted

  Published as AU-B-2005294269

24 November 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005294275-Immunogenic and therapeutic compositions for Streptococcus pyogenes

2005294265-Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway